Scholarlink

<p>Cell therapy with tumor-infiltrating lymphocytes (TILs) has yielded durable responses for multiple cancer types, but the causes of therapeutic resistance remain largely unknown. Here multidimensional analysis was performed on time-serial tumor and blood in a lung cancer TIL therapy trial. Using T cell receptor sequencing on both functionally expanded T cells and neoantigen-loaded tetramer-sorted T cells, we identified tumor antigen-specific T cell receptors. We then mapped clones into individual transcriptomes and found that tumor-reactive clonotypes expressed a dysfunctional program and lacked stem-like features among patients who lacked clinical benefit. Tracking tumor-reactive clonotypes over time, decay of antigen-reactive peripheral T cell clonotypes was associated with the emergence of progressive disease. Further, subclonal neoantigens previously targeted by infused T cells were subsequently absent within tumors at progression, suggesting potential adaptive resistance. Our findings suggest that targeting clonal antigens and circumventing dysfunctional states may be important for conferring clinical responses to TIL therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy

  • 期刊论文

  • 发表日期：

    2025年5月8日

查看全文
  • Chao Wang,
  • Xiaoqing Yu,
  • Jamie K. Teer,
  • Jiqiang Yao,
  • Dongliang Du,
  • Xiaoxian Liu,
  • Zachary J. Thompson,
  • Min Hsuan Wang,
  • Eric A. Welsh,
  • Danish Memon,
  • Timothy A. Chan,
  • Vladimir Makarov,
  • Carmen M. Anadon,
  • Lamees Saeed,
  • Theresa A. Boyle,
  • Bin Fang,
  • John M. Koomen,
  • Cheryl Cox,
  • Ana M. Landin,
  • Sean J. Yoder,
  • Sungjune Kim,
  • Dung-Tsa Chen,
  • Shari A. Pilon-Thomas,
  • Jose R. Conejo-Garcia,
  • Scott J. Antonia,
  • Eric B. Haura,
  • Benjamin C. Creelan

摘要

Cell therapy with tumor-infiltrating lymphocytes (TILs) has yielded durable responses for multiple cancer types, but the causes of therapeutic resistance remain largely unknown. Here multidimensional analysis was performed on time-serial tumor and blood in a lung cancer TIL therapy trial. Using T cell receptor sequencing on both functionally expanded T cells and neoantigen-loaded tetramer-sorted T cells, we identified tumor antigen-specific T cell receptors. We then mapped clones into individual transcriptomes and found that tumor-reactive clonotypes expressed a dysfunctional program and lacked stem-like features among patients who lacked clinical benefit. Tracking tumor-reactive clonotypes over time, decay of antigen-reactive peripheral T cell clonotypes was associated with the emergence of progressive disease. Further, subclonal neoantigens previously targeted by infused T cells were subsequently absent within tumors at progression, suggesting potential adaptive resistance. Our findings suggest that targeting clonal antigens and circumventing dysfunctional states may be important for conferring clinical responses to TIL therapy.